Highlights Newsletter 2
This newsletter presents you the following key sessions:
2. Long-term efficacy of amivantamab in pretreated NSCLC patients with EGFR exon 20 insertion mutations
3. Taletrectinib confirms its safety and efficacy in patients with ROS1+ non-small cell lung cancer